retatrutide microdosing Extreme Side Effects Followed Overdose of Unapproved Weight-Loss Drug Triple hormone receptor agonist retatrutide

In 2024 semaglutide (Wegovy) became the first weight loss drug to also be approved for the reduction of risk of serious cardiovascular events in patients with cardiovascular (CV) disease and obesity and overweight

A flowchart outlining the data extraction and patient selection process is provided in Supplemental Fig

In August 2025, Teva launched the first generic of liraglutide (Saxenda) for weight loss in adults and adolescents

Stop taking semaglutide immediately and do not resume without explicit guidance from your healthcare provider

ASGE Standards of Practice CommitteeEarlyDSLightdaleJRVargoJJIIAcostaRDChandrasekharaVet al

It helps prevent damage caused by free radicals, and helps maintain vitamin C and E levels